Abstract | BACKGROUND: METHODS: Rats aged 4 weeks were randomly assigned into three groups (n = 10 for each group): Group 1 (control), SHRs without treatment; Group 2 ( L-NAME), SHRs received L-NAME (80 mg/L) in drinking water; and Group 3 (L-NAME + melatonin), SHRs received L-NAME (80 mg/L) and 0.01% melatonin in drinking water. All rats were sacrificed at 10 weeks of age. RESULTS: CONCLUSION: Our results indicated that L-NAME/SHR is a useful model for hypertensive nephrosclerosis in young rats. The blood pressure-lowering and renoprotective effects of melatonin is due to increases of DDAH activity, decreases of ADMA, and reduction of oxidative stress in L-NAME-treated SHR kidney. Specific therapy targeting the DDAH-ADMA pathway may be a promising approach to slowing chronic kidney disease progression in children.
|
Authors | Ming-Chou Cheng, Ting-Hsin Wu, Li-Tung Huang, You-Lin Tain |
Journal | Pediatrics and neonatology
(Pediatr Neonatol)
Vol. 55
Issue 3
Pg. 189-95
(Jun 2014)
ISSN: 2212-1692 [Electronic] Singapore |
PMID | 24268813
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2013. Published by Elsevier B.V. |
Chemical References |
- Antioxidants
- arginine methyl ester
- Nitric Oxide
- N,N-dimethylarginine
- 8-Hydroxy-2'-Deoxyguanosine
- Arginine
- Nitric Oxide Synthase
- Amidohydrolases
- dimethylargininase
- Deoxyguanosine
- Melatonin
- NG-Nitroarginine Methyl Ester
|
Topics |
- 8-Hydroxy-2'-Deoxyguanosine
- Amidohydrolases
(metabolism)
- Animals
- Antioxidants
(pharmacology)
- Arginine
(analogs & derivatives, metabolism)
- Blood Pressure
(drug effects)
- Deoxyguanosine
(analogs & derivatives)
- Humans
- Hypertension
(metabolism, prevention & control)
- Hypertension, Renal
(metabolism, prevention & control)
- Kidney
(enzymology)
- Male
- Melatonin
(pharmacology)
- NG-Nitroarginine Methyl Ester
(toxicity)
- Nephritis
(metabolism, prevention & control)
- Nitric Oxide
(metabolism)
- Nitric Oxide Synthase
(metabolism)
- Rats
- Rats, Inbred SHR
|